FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesEAP 104: EAP Communication and Stakeholder Management
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Presentation
Members
2023 US Conference - Sponsorship and Exhibitor Overview
Topic: Conference
Video
Free
GCSG Presentation Tips from Steve Jacobs
Topics: Communication, Personal Development
Conference Training
Members
